Kymera Therapeutics, Inc. KYMR recently announced that the FDA granted Fast Track designation to pipeline candidate KT-621 for the treatment of moderate to severe atopic dermatitis (AD), the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback